Douglas J. Sheffler

4.8k total citations · 2 hit papers
63 papers, 3.6k citations indexed

About

Douglas J. Sheffler is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Oncology. According to data from OpenAlex, Douglas J. Sheffler has authored 63 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Molecular Biology, 38 papers in Cellular and Molecular Neuroscience and 5 papers in Oncology. Recurrent topics in Douglas J. Sheffler's work include Receptor Mechanisms and Signaling (40 papers), Neuroscience and Neuropharmacology Research (29 papers) and Pharmacological Receptor Mechanisms and Effects (10 papers). Douglas J. Sheffler is often cited by papers focused on Receptor Mechanisms and Signaling (40 papers), Neuroscience and Neuropharmacology Research (29 papers) and Pharmacological Receptor Mechanisms and Effects (10 papers). Douglas J. Sheffler collaborates with scholars based in United States, Australia and Germany. Douglas J. Sheffler's co-authors include Bryan L. Roth, Wesley K. Kroeze, P. Jeffrey Conn, Nicholas D. P. Cosford, Craig W. Lindsley, Marilyn A. Davies, Raveendra-Panickar Dhanya, Mitchell Vamos, Reuben J. Shaw and Anushree Bhatnagar and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Molecular Cell.

In The Last Decade

Douglas J. Sheffler

60 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

2004 893 citations Bryan L. Roth, Douglas J. Sheffler et al. profile →
Small Molecule Inhibition of the Autophagy Kinase ULK1 and Identification of ULK1 Substrates

2015 559 citations Matthew G. H. Chun, Mitchell Vamos et al. Molecular Cell profile →

Peers

Countries citing papers authored by Douglas J. Sheffler

Since Specialization

Citations

This map shows the geographic impact of Douglas J. Sheffler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas J. Sheffler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas J. Sheffler more than expected).

Fields of papers citing papers by Douglas J. Sheffler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas J. Sheffler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas J. Sheffler. The network helps show where Douglas J. Sheffler may publish in the future.

Co-authorship network of co-authors of Douglas J. Sheffler

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas J. Sheffler. A scholar is included among the top collaborators of Douglas J. Sheffler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas J. Sheffler. Douglas J. Sheffler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	17β-estradiol status alters NMDAR function and antipsychotic-like activity in female rats 2025 ·Molecular Psychiatry ·(unknown), (unknown), (unknown), C. Moriarty, (unknown), (unknown), (unknown), Douglas J. Sheffler, (unknown), Heather A. Bimonte‐Nelson, Kimberly F. Raab‐Graham, Robert W. Gould	0
2	Sex-dependent role of Neuropeptide-S on anxiety, fear conditioning, and alcohol seeking in alcohol preferring rats 2025 ·Neuropharmacology ·Min Li, (unknown), Laura Soverchia, Scott P. Runyon, Stewart D. Clark, Marisa Roberto, Carolina L. Haass‐Koffler, Roberto Ciccocioppo, Douglas J. Sheffler, Nazzareno Cannella	0
3	Fragment Screening Identifies Novel Allosteric Binders and Binding Sites in the VHR (DUSP3) Phosphatase 2025 ·ACS Omega ·(unknown), (unknown), Alexander E. Aleshin, (unknown), Lester J. Lambert, (unknown), (unknown), Ranajit Das, Douglas J. Sheffler, Andrey A. Bobkov, (unknown), D.A. Keedy, Nicholas D. P. Cosford, Lutz Tautz	4
4	Inhibitors of the Hippo Pathway Kinases STK3/MST2 and STK4/MST1 Have Utility for the Treatment of Acute Myeloid Leukemia 2021 ·Journal of Medicinal Chemistry ·(unknown), A. Chaikuad, (unknown), Allison S. Limpert, Lester J. Lambert, Douglas J. Sheffler, Lena M. Berger, (unknown), (unknown), Li Wang, Yi Peng, Jing Dong, Maria Celeridad, (unknown), Stefan Knapp, Nicholas D. P. Cosford	23
5	Identification and Development of a New Positron Emission Tomography Ligand 4-(2-Fluoro-4-[¹¹C]methoxyphenyl)-5-((1-methyl-1H-pyrazol-3-yl)methoxy)picolinamide for Imaging Metabotropic Glutamate Receptor Subtype 2 (mGlu₂) 2020 ·Journal of Medicinal Chemistry ·Tomoteru Yamasaki, Xiaofei Zhang, Katsushi Kumata, Yiding Zhang, Xiaoyun Deng, Masayuki Fujinaga, Zhen Chen, Wakana Mori, Kuan Hu, Hidekatsu Wakizaka, Akiko Hatori, Lin Xie, Masanao Ogawa, Nobuki Nengaki, Richard Van, Yihan Shao, Douglas J. Sheffler, Nicholas D. P. Cosford, Steven H. Liang, Ming‐Rong Zhang	4
6	Co-Activation of Metabotropic Glutamate Receptor 3 and Beta-Adrenergic Receptors Modulates Cyclic-AMP and Long-Term Potentiation, and Disrupts Memory Reconsolidation 2017 ·Neuropsychopharmacology ·Adam G. Walker, Douglas J. Sheffler, Andrew Lewis, Jonathan W. Dickerson, Daniel J. Foster, (unknown), Mark S. Moehle, Xiaohui Lv, Branden J. Stansley, Zixiu Xiang, Jerri M. Rook, Kyle A. Emmitte, Craig W. Lindsley, P. Jeffrey Conn	16
7	Screening for Small Molecule Inhibitors of Statin-Induced APP C-terminal Toxic Fragment Production 2017 ·Frontiers in Pharmacology ·Karen S. Poksay, Douglas J. Sheffler, Patricia Spilman, Jesus Campagna, (unknown), Olivier Descamps, Olivia Gorostiza, (unknown), Michael C. Mullenix, Dale E. Bredesen, Nicholas D. P. Cosford, Varghese John	3
8	Application of Parallel Multiparametric Cell-Based FLIPR Detection Assays for the Identification of Modulators of the Muscarinic Acetylcholine Receptor 4 (M4) 2015 ·SLAS DISCOVERY ·Emery Smith, Peter Chase, Colleen M. Niswender, Thomas J. Utley, Douglas J. Sheffler, Meredith J. Noetzel, Atin Lamsal, Michael R. Wood, P. Jeffrey Conn, Craig W. Lindsley, Franck Madoux, (unknown), Louis Scampavia, Timothy Spicer, Peter Hodder	25
9	Small Molecule Inhibition of the Autophagy Kinase ULK1 and Identification of ULK1 Substrates breakdown → 2015 ·Molecular Cell ·(unknown), Matthew G. H. Chun, Mitchell Vamos, Haixia Zou, Juan Rong, Chad J. Miller, Hua Jane Lou, Raveendra-Panickar Dhanya, Chih-Cheng Yang, Douglas J. Sheffler, Peter Teriete, John M. Asara, Benjamin E. Turk, Nicholas D. P. Cosford, Reuben J. Shaw	559
10	Design and Synthesis of Systemically Active Metabotropic Glutamate Subtype-2 and -3 (mGlu_2/3) Receptor Positive Allosteric Modulators (PAMs): Pharmacological Characterization and Assessment in a Rat Model of Cocaine Dependence 2014 ·Journal of Medicinal Chemistry ·Raveendra-Panickar Dhanya, Douglas J. Sheffler, Russell Dahl, (unknown), (unknown), Li Yang, Hilary Highfield Nickols, Hyekyung P. Cho, Layton H. Smith, Manoranjan S. D’Souza, P. Jeffrey Conn, Andre Der‐Avakian, Athina Markou, Nicholas D. P. Cosford	26
11	Isatin replacements applied to the highly selective, muscarinic M1 PAM ML137: Continued optimization of an MLPCN probe molecule 2012 ·Bioorganic & Medicinal Chemistry Letters ·Bruce J. Melancon, Michael S. Poslusney, Patrick R. Gentry, James C. Tarr, Douglas J. Sheffler, Margrith E. Mattmann, Thomas M. Bridges, Thomas J. Utley, J. Scott Daniels, Colleen M. Niswender, P. Jeffrey Conn, Craig W. Lindsley, Michael R. Wood	17
12	Development of a more highly selective M1 antagonist from the continued optimization of the MLPCN Probe ML012 2011 ·Bioorganic & Medicinal Chemistry Letters ·Bruce J. Melancon, (unknown), Thomas M. Bridges, Gary A. Sulikowski, Thomas J. Utley, Douglas J. Sheffler, Meredith J. Noetzel, Ryan D. Morrison, (unknown), Colleen M. Niswender, Carrie K. Jones, (unknown), (unknown), Michael R. Wood	6
13	Design and Synthesis of an Orally Active Metabotropic Glutamate Receptor Subtype-2 (mGluR2) Positive Allosteric Modulator (PAM) That Decreases Cocaine Self-Administration in Rats 2010 ·Journal of Medicinal Chemistry ·Raveendra-Panickar Dhanya, Shyama Sidique, Douglas J. Sheffler, Hilary Highfield Nickols, Ananda Herath, Li Yang, Russell Dahl, Robert Ardecky, Svetlana Semenova, Athina Markou, P. Jeffrey Conn, Nicholas D. P. Cosford	36
14	mGluR5 Positive Allosteric Modulators Facilitate both Hippocampal LTP and LTD and Enhance Spatial Learning 2009 ·Neuropsychopharmacology ·Jennifer Ayala, Yelin Chen, Jessica L. Banko, Douglas J. Sheffler, Richard D. Williams, (unknown), Noreen L Watson, Zixiu Xiang, Yongqin Zhang, Paulianda J. Jones, Craig W. Lindsley, M. Foster Olive, P. Jeffrey Conn	177
15	Novel allosteric modulators of metabotropic glutamate receptors subtypes 2 and 5 for the treatment of schizophrenia 2008 ·Neuropharmacology ·Carrie K. Jones, Fangfang Xiang, Andrew K. Jones, Nellie Byun, (unknown), (unknown), Jennifer Ayala, Colleen M. Niswender, Satyawan Jadhav, Douglas J. Sheffler, Alexis S. Hammond, (unknown), A.K. Thompson, Richard D. Williams, (unknown), C. David Weaver, Craig W. Lindsley, P. Jeffrey Conn	1
16	mGlur5 positive allosteric modulators facilitate both LTP and LTD induction in the rat hippocampal CA1 region 2008 ·Neuropharmacology ·(unknown), Yunan Chen, Jessica L. Banko, Douglas J. Sheffler, Richard D. Williams, P. Jeffrey Conn	1
17	Synthesis and SAR of selective muscarinic acetylcholine receptor subtype 1 (M1 mAChR) antagonists 2008 ·Bioorganic & Medicinal Chemistry Letters ·L. Michelle Lewis, Douglas J. Sheffler, Richard D. Williams, Thomas M. Bridges, J. Phillip Kennedy, John T. Brogan, (unknown), (unknown), (unknown), Colleen M. Niswender, (unknown), P. Jeffrey Conn, Craig W. Lindsley	12
18	Ribosomal S6 Kinase 2 Directly Phosphorylates the 5-Hydroxytryptamine 2A (5-HT2A) Serotonin Receptor, Thereby Modulating 5-HT2A Signaling 2008 ·Journal of Biological Chemistry ·Ryan T. Strachan, Douglas J. Sheffler, Belinda Willard, Michael Kinter, Janna Kiselar, Bryan L. Roth	32
19	Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology 2004 ·CNS Drug Reviews ·Marilyn A. Davies, Douglas J. Sheffler, Bryan L. Roth	129
20	Cell-Type Specific Effects of Endocytosis Inhibitors on 5-Hydroxytryptamine_2AReceptor Desensitization and Resensitization Reveal an Arrestin-, GRK2-, and GRK5-Independent Mode of Regulation in Human Embryonic Kidney 293 Cells 2001 ·Molecular Pharmacology ·J.A. Gray, Douglas J. Sheffler, Anushree Bhatnagar, (unknown), Sandra J. Hufeisen, Jeffrey Benovic, (unknown)	74

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact